Clinical Trial Update: ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating ONT01 in combination with gemcitabine and nab-paclitaxel as second-line therapy for metastatic pancreatic ductal adenocarcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• ONT01 (ONT01)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING